Semaglutide is a GLP-1 receptor agonist
Semaglutide, marketed under brand names including Ozempic, Wegovy, and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management and chronic weight management
It's important to note that semaglutide is not recommended for patients with severe gastroparesis, as it may further delay gastric emptying and worsen symptoms
Studies show that GLP-1 medications can impact gastric motility, which can contribute to symptoms like bloating and side effects like sulfur burps, especially in people who are sensitive to changes in their digestion
Users with pre-existing IBS Irritable bowel syndrome affects approximately 10-15% of the global population, and many IBS sufferers also seek treatment for weight management
One of the primary effects of GLP-1 receptor activation is slowing gastric motility